Adverum Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. NAVN
9. DFTX
10. IBM

Go back to Adverum Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema

RBC Capital Downgrades Adverum Biotechnologies (ADVM) to Sector Perform

April 29, 2021 6:18 AM EDT

RBC Capital analyst Luca Issi downgraded Adverum Biotechnologies (NASDAQ: ADVM) from Outperform to Sector Perform with a price target of $6.00 (from $30.00).

The analyst comments "ADVM announced a serious adverse event of hypotony (decreased intraocular pressure), panuveitis and loss of vision in a DME... More